Immuron: IMM124E – Demonstrates antiviral immunity against T cells – Form 6-K


IMM124E – Demonstrates antiviral immunity of T cells

Key points

International patent filed

Publication of the Hebrew University – Hadassah Medical Center Title: Augmented antiviral T cell Immunity by oral administration of IMM-124E in preclinic models and a phase I / IIa clinical trial: A method for the prevention and treatment of COVID-19

Melbourne, Australia, October 8, 2021: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on the development and commercialization of oral immunotherapeutics for the prevention and treatment of intestinal pathogens, is pleased to ” inform its shareholders of a recent publication describing the potential antiviral benefits of IMM-124E in a mouse model and a human clinical study. IMM124E, the Company’s proprietary product, is used to manufacture Immuron’s flagship commercial and over-the-counter gastrointestinal and digestive health immune supplements, Travelan® and Protectyn®. The studies were conducted independently by the Hadassah Medical Center, Jerusalem Israel.

The research results were recently published on 1st of October 2021 in the Journal Drug Development Research entitled Augmented antiviral T cell Immunity by oral administration of IMM-124E in preclinic models and a phase I / IIa clinical trial: A method for the prevention and treatment of COVID-19 (https: / / doi.org/10.1002/ddr.21890). The article examines the ability of IMM-124E to promote antiviral T cell responses to interferon-γ (IFNγ) in a preclinical mouse model and in a phase I / IIa clinical study in 5 humans. health volunteers. The objective of the research study was to determine the ability of IMM-124E to promote the responses of antiviral T cells to interferon γ (IFNγ). In the preclinical study, mice were administered orally with HBC for 5 days and tested for the number of T cell clones secreting IFNγ in response to the viral antigens of swine flu, Nova flu – Caledonia and cytomegalovirus. The reported data suggest that IMM124E improves antiviral immunity among the viral strains tested. A similar response was observed in the human study. Healthy volunteers were recruited and received IMM-124E at a daily dose of 600 mg for four consecutive days and 1200 mg for an additional day. Blood samples were taken before and after treatment with IMM-124E and tested for the number of T cell clones secreting IFNγ in response to viral antigens of SARS-CoV-2 and hepatitis B virus. The data Preliminary reported clinics suggest that a similar effect has been observed in humans by increasing antiviral responses against COVID-19 and hepatitis B. Although more in-depth and detailed investigations are needed to further validate the results, it is This is very encouraging research.

The company continued the antiviral activities of IMM-124E and these recent published results support the ongoing R&D program. Immuron previously reported research on IMM-124E that demonstrated neutralizing activity against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19 (ASX announcements dated May 13, 2021, December 15, 2020 and July 21, 2020).

The company is also pleased to announce that it has filed a patent cooperation (PCT) patent application to seek international patent protection for IMM-124E which has demonstrated neutralizing activity against the coronavirus. -2 Severe Acute Respiratory Syndrome (SARS-CoV-2), the virus that causes COVID-19.

This press release has been authorized by the directors of Immuron Limited.

– – – TO FINISH – – –

Level 3, 62 Lygon Street,

Carlton South, Victoria

AUSTRALIA 3,053

www.immuron.com

ABN: 80 063 114 045

Telephone:

Facsimile:


+ 61 (0) 3 9824 5254
+ 61 (0) 3 9822 7735

COMPANY CONTACT:

Dr Jerry Kanellos, Ph.D.

Chief Executive Officer

Phone. : +61 (0) 3 9824 5254

[email protected]

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN) is an Australian biopharmaceutical company specializing in the development and commercialization of targeted polyclonal antibodies administered orally for the treatment of inflammatory and infectious diseases. Immuron has a new and secure technology platform with an income generating business asset. In Australia, Travelan® is a drug listed in the Australian Therapeutic Products Registry (AUST L 106709) and is indicated to reduce the risk of traveler’s diarrhea, reduce the risk of minor gastrointestinal disturbances and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of traveler’s diarrhea. In the United States, Travelan® is sold as a dietary supplement for the protection of the digestive tract in accordance with Section 403 (r) (6) of the Federal Drug Administration (FDA).

About Travelan®

Travelan® is an oral passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea, a disorder of the digestive tract that is usually caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tablet formulation of hyperimmune bovine antibodies and other factors which, when taken with meals, bind to bacteria causing diarrhea and prevent colonization and pathology associated with traveler’s diarrhea. . In Australia, Travelan® is a drug listed in the Australian Therapeutic Products Registry (AUST L 106709) and is indicated to reduce the risk of traveler’s diarrhea, reduce the risk of minor gastrointestinal disturbances and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of traveler’s diarrhea. In the United States, Travelan® is sold as a dietary supplement for the protection of the digestive tract.

About traveler’s diarrhea

Travelers’ diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and sometimes bloody) stools, abdominal cramps, bloating, and fever. Enteropathogenic bacteria are responsible for most cases, along with enterotoxin Escherichia coli (ETEC) playing a dominant causal role. Campylobacter spp. are also responsible for a significant proportion of cases. The most serious infections with Salmonella spp. bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with traveller’s diarrhea as they can be contracted during travel and the first symptoms are often indistinguishable.

For more information visit: http://www.immuron.com

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, without limitation, any statement relating to our growth strategy and product development programs and any other statements which are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and the value of our shares. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; our ability to secure, execute and maintain funding and strategic agreements and relationships; risks linked to the results of research and development activities; risks associated with the timing of the initiation and completion of clinical trials; uncertainties relating to preclinical and clinical trials; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the initial stage of products under development; our need for substantial additional funds; government regulations; patent and intellectual property issues; competetion; as well as other risks described in our filings with the SEC. We expressly disclaim any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statement is based, unless required by law.

Page 2 of 2

Disclaimer

Immuron Limited published this content on 08 October 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on 08 October 2021 10:11:04 AM UTC.

Previous Immutep Limited (ASX: IMM): Are analysts optimistic?
Next High Court orders pay only 70% of tuition fee for transfer certificate to private schools

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *